Julian Heuberger et al EMBO Molecular Medicine

Expanded View Figures




Figure EV1.

EMBO Molecular Medicine Julian Heuberger et al

Figure EV1. Differentiation of colon organoids after IFN- γ treatment.

A Quantification of KRT20 immunofluorescence of human colon organoids cultured either in full or basic medium and treated with IFN- γ . Left: relative abundance of KRT20⁺ cells per organoid; Right: Fluorescence intensity of KRT20⁺ cells, indicating an increase in KRT20 expression in response to IFN- γ . Data are presented as mean \pm SD, *: $P \le 0.05$, **: $P \le 0.001$, ***: $P \le 0.0001$, as determined by one-way ANOVA, followed by Tukey's multiple comparisons test (more details see Appendix Table S2).

- B Measurement of IFN-γ responsiveness by qRT–PCR for the IFN-γ target gene IFIT3 at concentrations from 5 pg/ml to 100 ng/ml.
- C Immunofluorescence staining for E-cadherin (green) and actin (red) of organoids grown in full medium (left) or basic medium (right) and additionally treated with IFN- γ (lower), indicating increased columnar cell height as a feature of differentiation upon IFN- γ treatment. Scale bar: 25 μ m. Quantification of cell length on the right. Data are presented as mean \pm SD, *: $P \le 0.05$, **: $P \le 0.001$, ***: $P \le 0.0001$, as determined by one-way ANOVA, followed by Tukey's multiple comparison test (more details see Appendix Table S2).
- D Alcian blue–nuclear fast red staining of human colon organoids cultured in full medium (upper panel) or differentiation medium (lower panel), with or without IFN-γ treatment to visualize goblet cells. Scale bar: 50 μm.
- E Comparison of the differentiation markers ALPI (enterocytes, left) and ITF (goblet cells, right) in organoids grown in full medium or in basic medium and either untreated or treated with IFN- γ . Data are presented as mean \pm SD, *: $P \le 0.005$, **: $P \le 0.001$, ***: $P \le 0.0001$, as determined by one-way ANOVA followed by Tukey's multiple comparison test.

Figure EV2. Interferon-γ (IFN-γ) induces differentiation into enterocytes and upregulates Ace2 expression in murine colon organoids.

- A Immunofluorescence for Ace2 (red) and Krt20 (green) in murine colon: pronounced expression of *Ace2* in terminally differentiated surface enterocytes at the top of the colon crypt. Magnifications of single fluorescence channels below. Scale bar: 50 µm.
- B t-sne plot for selected genes from single-cell RNAseq of mouse colon revealing expression of *Krt20* in enterocytes (Car4⁺ population) and partially in goblet cells (Tff3⁺ population). Interferon receptors (Ifngr1/2) show rather broad expression in the mouse colon epithelium.
- C 3-dimensional organoid culture from mouse colon epithelium using different culture conditions; upper: full medium (Full), middle: upon Wnt withdrawal (-Wnt, CHIR (-WC)), lower: FM supplemented with IFN -γ (Ifn-γ). Immunofluorescence for Krt20 (green) middle panel, and immunofluorescence for E-cadherin (green), third from right, and phalloidin staining for actin (right) Scale bar: 50 μm. Magnification of IFN-γ-treated organoids stained for Krt20 and E-cadherin below.
- D Western blot of protein lysates from mouse colon organoids cultured in full medium or treated with IFN-γ, showing increase of Krt20 protein upon IFN-γ treatment. Tubulin served as loading control.
- E Optical section of whole mount immunofluorescence of 2 h EdU incorporation (red) in organoids cultured in full medium, -WC medium or treated with IFN- γ to label proliferating cells in s-phase. Right: quantification of EdU-positive nuclei as percentage of all nuclei per organoid. Data are presented as mean \pm SD, *: $P \le 0.001$, ***: $P \le 0.001$, ***: $P \le 0.0001$, as determined by one-way ANOVA, followed by Tukey's multiple comparison test (more details see Appendix Table S2).
- F Comparison of *Krt20* mRNA expression of control (full medium) and IFN-γ-treated organoids, as determined by qPCR. Data are presented as mean ± SD *: P ≤ 0.05, **: P ≤ 0.001, as determined by Student's *t*-test (more details see Appendix Table S2).

EV2 *EMBO Molecular Medicine* 13: e13191 | 2021 © 2021 The Authors

Julian Heuberger et al EMBO Molecular Medicine





Figure EV2.

EMBO Molecular Medicine Julian Heuberger et al







Figure EV3. Infection of air-liquid interface culture and tracking of SARS-CoV-2-infected organoids.

- A Air–liquid interface culture of human colonocytes. Immunofluorescence for KRT20 (green) and E-cadherin (red), indicating differentiated epithelial cells. Right: qPCR data displaying the relative virus load of SARS-CoV-2 measured by viral genome quantity in ALI cells, normalized to GAPDH. Data are presented as mean ± SD, **: P ≤ 0.01, as determined by Student's t-test (more details see Appendix Table S2).
- B Bright field images of human colon organoids cultured in full medium (left), full medium + IFN-γ (second right), differentiated (third right) and differentiated + IFN-γ (far right), either uninfected (upper panel), or after 24 h (middle panel) or 48 h (lower panel) post-infection with SARS-CoV-2. Scale bar: 50 μm.

EMBO Molecular Medicine 13: e13191 | 2021 © 2021 The Authors

Iulian Heuberaer et al EMBO Molecular Medicine






Figure EV4. Analysis of pan-JAK inhibition upon IFN- γ treatment and SARS-CoV-2 infection.

A qPCR data of differentiated and SARS-CoV-2-infected human colon organoids treated with the pan-JAK inhibitor pyridone-6 (P6). Data generated from four biological replicates from two patients. Median with interquartile range. Data indicating decreased expression of *ACE2, KRT20, CXCL11*, and *IFIT3 upon* P6 treatement. Data are presented as mean \pm SD, *: $P \le 0.05$, **: $P \le 0.001$, ***: $P \le 0.001$, as determined by Student's t-test (more details see Appendix Table S2).

B qPCR data comparing the relative virus load of SARS-CoV-2 measured by viral genome quantity normalized to *GAPDH* at 48 h after infection in basic medium untreated and treated with IFN-γ and pyridone-6, indicating that IFN-γ increases virus load, which is reduced upon inhibition of JAK kinases. Data assessed from two different patient samples are shown.